AI Stock Analysis - BioXcel Therapeutics (BTAI)
Analysis generated August 26, 2025.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company focused on utilizing artificial intelligence (AI) to enhance the drug discovery and development process. The company's core pipeline includes treatments for neurological and immuno-oncology diseases, with its most prominent product being BXCL501, an orally dissolvable thin film formulation of dexmedetomidine targeting agitation in various neuropsychiatric conditions. With an AI-driven platform, BioXcel aims to reduce drug development timelines and enhance therapeutic innovations.
Stock Alerts - BioXcel Therapeutics (BTAI)
 |
BioXcel Therapeutics | March 10 Price is down by -9.8% in the last 24h. |
|
BioXcel Therapeutics | March 9 Price is up by 6.1% in the last 24h. |
|
BioXcel Therapeutics | March 6 Price is down by -6.8% in the last 24h. |
|
BioXcel Therapeutics | March 5 Price is up by 6.7% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for BioXcel Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 107 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,863 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 27 | Sign up | Sign up | Sign up |
| Linkedin Employees | 59 | Sign up | Sign up | Sign up |
About BioXcel Therapeutics
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
| Price | $1.49 |
| Target Price | Sign up |
| Volume | 2,258,251 |
| Market Cap | $33M |
| Year Range | $1.31 - $6.8 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingMarch 11 - GlobeNewswire |
|
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingMarch 10 - GlobeNewswire |
|
BioXcel Therapeutics To Hold Virtual KOL Roundtable On February 27 Highlighting ~100M Annual Alzheimer's Agitation Episodes And Lack Of FDA-Approved TreatmentsFebruary 18 - Benzinga |
|
BioXcel Therapeutics Reports Strong Prescriber Interest, Patient Demand, And Positive Payer Feedback Supporting Broad Formulary Coverage For IGALMI In The Acute Treatment Of AgitationFebruary 11 - Benzinga |
|
 |
BioXcel Therapeutics submits sNDA to U.S. FDA for IgalmiJanuary 20 - Thefly.com |
 |
BioXcel Therapeutics appoints Pavao as acting CCOJanuary 12 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 98,000 | 86,000 | 12,000 | -31M | -26M | -2.180 |
| Q2 '25 | 120,000 | 110,000 | 13,000 | -19M | -15M | -2.450 |
| Q1 '25 | 170,000 | 14,000 | 150,000 | -7.3M | -3.2M | -1.500 |
| Q4 '24 | 370,000 | 830,000 | -470,000 | -11M | -6.8M | -3.563 |
| Q3 '24 | 210,000 | 1.2M | -960,000 | -14M | -9.8M | -0.320 |
Insider Transactions View All
| Yocca Frank filed to sell 29,156 shares at $0.4. December 17 '24 |
| Yocca Frank filed to sell 28,931 shares at $0.4. December 17 '24 |
| Rodriguez Javier filed to sell 24,643 shares at $0.4. December 17 '24 |
| Rodriguez Javier filed to sell 24,423 shares at $0.4. December 17 '24 |
| Steinhart Richard I filed to sell 21,157 shares at $0.4. December 17 '24 |
Similar companies
Read more about BioXcel Therapeutics (BTAI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - BioXcel Therapeutics
The Market Cap of BioXcel Therapeutics is $33M.
Currently, the price of one share of BioXcel Therapeutics stock is $1.49.
The BTAI stock price chart above provides a comprehensive visual representation of BioXcel Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BioXcel Therapeutics shares. Our platform offers an up-to-date BTAI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, BioXcel Therapeutics (BTAI) does not offer dividends to its shareholders. Investors interested in BioXcel Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of BioXcel Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
